featured
ESMO 2018: Nivolumab Plus Ipilimumab in First-line Setting for MSI-H Metastatic Colon Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles: